What is BioLargo?
Founded in 1989 and headquartered in Westminster, BioLargo operates at the intersection of environmental engineering and industrial biotechnology. The firm specializes in the development and commercialization of innovative solutions, including its Advanced Oxidation System (AOS), CupriDyne, and the Isan system. These technologies serve a diverse array of sectors, ranging from wastewater treatment and food processing to healthcare, agriculture, and the oil and gas industry. Beyond its core industrial applications, BioLargo maintains a consumer-facing presence through its Odor-No-More and Natures Best Solution product lines, which address odor and moisture control. The company's business model is defined by its ability to translate complex scientific research into scalable, market-ready products that address critical regulatory and operational needs across global markets.
How much funding has BioLargo raised?
BioLargo has raised a total of $7.2M across 9 funding rounds:
Debt
$681K
Debt
$1.1M
Debt
$978K
Debt
$1.1M
Debt
$700K
Debt
$862K
Debt
$150K
Stock/Share Issuance
$887K
Debt (2009): $681K, investors not publicly disclosed
Debt (2010): $1.1M, investors not publicly disclosed
Debt (2011): $978K, investors not publicly disclosed
Debt (2012): $1.1M, investors not publicly disclosed
Debt (2013): $700K, investors not publicly disclosed
Debt (2013): $862K, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Stock/Share Issuance (2026): $887K, investors not publicly disclosed
Key Investors in BioLargo
Undisclosed Investor
Undisclosed investor participating in the funding round.
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BioLargo?
With the infusion of $887K, BioLargo is well-positioned to accelerate the commercial deployment of its flagship technologies. The strategic focus will likely shift toward scaling production capabilities and expanding market penetration for its water treatment and disinfection dosing systems. As the company moves into this next phase of growth, the emphasis will remain on optimizing operational efficiencies and strengthening its intellectual property moat. Investors are closely monitoring the firm's ability to convert its diverse technological pipeline into sustained revenue streams, particularly as global demand for sustainable water management and industrial hygiene solutions continues to intensify. The company's long-term trajectory suggests a transition from research-heavy development toward high-volume commercialization, supported by a disciplined approach to capital allocation and strategic market expansion.
See full BioLargo company page
